Online citations, reference lists, and bibliographies.
← Back to Search

Brain Metastasis Of Patients With Lung Adenocarcinoma: Epidermal Growth Factor Receptor Mutations And Response To Whole-Brain Radiation Therapy

S. Wu, Jin-Yuan Shih
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Brain metastases develop frequently in non-small cell lung cancers (NSCLC), and cause poor prognosis and rapid deterioration in neurologic function. Whole brain radiotherapy (WBRT) is the standard treatment for brain metastasis. Epidermal growth factor receptor (EGFR) is a determinant factor for the radiation response of cells. Overexpression of EGFR results in radioresistance, and non-homologous end-joining (NHEJ) plays an important role for repair of radiation-induced DNA damage. However, EGFR mutation cell lines show radiosensitive characteristics. After radiation, mutant EGFR could not translocate to the nucleus and failed to bind to the DNA-dependent protein kinase. This reduces radioresistance to lung cancer cell lines. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be active on brain metastases in NSCLC patients. A combination of WBRT and EGFR-TKIs seems to result in a favorable response rate and better overall survival of lung cancer patients. Further advances in the understanding of the metastatic cascade and the mechanism of radiation-induced cell damage may lead to new treatment modalities and better survival for lung patients with metastatic brain disease.
This paper references
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
A. Barker (2001)
Whole-brain radiotherapy in the management of brain metastasis.
D. Khuntia (2006)
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
A. Eichler (2010)
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
K. Fujiwara (2003)
Multidisciplinary management of brain metastases.
A. Eichler (2007)
Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma.
A. Das (2007)
Epidermal growth factor receptor mutations in lung cancer
S. Sharma (2007)
Homologous recombination-mediated double-strand break repair.
C. Wyman (2004)
Brain metastases: Histology, multiplicity, surgery, and survival
E. Nussbaum (1996)
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.
J. Sørensen (1988)
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
R. Mak (2011)
Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation
R. Schmidt-Ullrich (1997)
The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage
D. Chen (2007)
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
Chi Wu (2007)
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.
C. Tsai (1993)
Mechanism of DNA double-strand break repair by non-homologous end joining.
Melissa L Hefferin (2005)
Radiation‐induced dementia in patients cured of brain metastases
L. DeAngelis (1989)
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R. Porta (2010)
An overview of radiotherapy trials for the treatment of brain metastases.
L. Berk (1995)
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
Shenglin Ma (2009)
The Biology of Epidermal Growth Factor Receptor in Lung Cancer
G. Scagliotti (2004)
Cancer statistics, 2011
R. Siegel (2011)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
K. Hotta (2004)
Signal transduction and oncogenesis by ErbB/HER receptors.
M. D. Marmor (2004)
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
S. Park (2009)
Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).
M. van Vulpen (2002)
Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation
T. Blunt (1995)
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
G. Ceresoli (2004)
Frequent EGFR mutations in brain metastases of lung adenocarcinoma
S. Matsumoto (2006)
Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Shyh-Min Huang (2002)
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
A. Das (2006)
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
C. Bianco (2002)
Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response
C. Gow (2008)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain
M. Jamal-Hanjani (2011)
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Yin-duo Zeng (2012)
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
S. Park (2012)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
T. Lynch (2004)
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.
A. Sancar (2004)
Phosphatidylinositide 3-kinase/AKT in radiation responses.
M. Zhan (2004)
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
F. Cappuzzo (2003)
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Shiaw-Yih Lin (2001)
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
Eric L. Chang (2009)
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
M. Mehta (2009)

Semantic Scholar Logo Some data provided by SemanticScholar